Aspirin may offer less survival benefit in patients with diabetes after acute coronary syndromes than in those without diabetes

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1629, 2008-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis

By  

Current Pharmaceutical Design, Vol. 24, Iss. 4, 2018-04 ,pp. : 465-477

Bentham Science Publishers

Access to resources Recommend Favorite

Optimising treatment after acute MI in patients with diabetes

By  

Inpharma, Vol. 1, Iss. 1272, 2001-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Patients' adherence to secondary prevention pharmacotherapy after acute coronary syndromes

By Kassab Yaman  

International Journal of Clinical Pharmacy, Vol. 35, Iss. 2, 2013-04 ,pp. : 275-280

Springer Publishing Company

Access to resources Recommend Favorite

Aspirin improves survival after coronary bypass surgery

By  

Inpharma, Vol. 1, Iss. 1362, 2002-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Defining the optimal dose of aspirin and clopidogrel in acute coronary syndromes

By Gurm Hitinder S   Eagle Kim A  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. : 149-151

Informa Healthcare

Access to resources Recommend Favorite